Phase 2 trial in 61 women with anogenital lichen sclerosus: 1.5% ruxolitinib cream did not improve itch v vehicle at week 12 (≥4-point Itch NRS gain 35.7% v 40.0%, P=.737), though Clinical Lichen Sclerosus Score fell more (-5.79 v -3.03).
RCTn = 61 patients
Goldstein et al. Efficacy and safety of ruxolitinib cream in patients with lichen sclerosus: Results from a phase 2, randomized, double-blind, vehicle-controlled study